17 results on '"Melani L"'
Search Results
2. Evaluation of staining betung bamboo (Dendrocalamus asper) using natural and synthetic dyes with and without the addition of preservatives
- Author
-
Al’Afifah, J A, primary, Sumardi, I, additional, Darwis, A, additional, Melani, L, additional, and Suhaya, Y, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Evaluation of staining betung bamboo (Dendrocalamus asper) using natural and synthetic dyes with and without the addition of preservatives.
- Author
-
Al'Afifah, J A, Sumardi, I, Darwis, A, Melani, L, and Suhaya, Y
- Published
- 2024
- Full Text
- View/download PDF
4. Geological and Geochemical Characterization of Salt-Bearing Sequences for Hydrogen Storage in the Delaware Basin (West Texas)
- Author
-
Martinez-Donate, A., primary, Moscardelli, L., additional, Ko, L., additional, Melani, L., additional, Schuba, N., additional, Bhattacharya, S., additional, and Ruiz Maraggi, L., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Trampolín: el diseño como herramienta de transformación social
- Author
-
Melani Lleonart García and Álvaro Sanchis
- Subjects
diseño social ,innovación social ,diseño inclusivo ,creatividad ,cocreación ,Visual arts ,N1-9211 ,Drawing. Design. Illustration ,NC1-1940 - Abstract
Entrevista a Yvette García y Javier La Casta Vilar, creadores de Trampolín, una plataforma creativa inclusiva que emplea la metodología y el pensamiento en diseño para elaborar proyectos sociales en torno a la creatividad. Su objetivo es ayudar a empresas, entidades y colectivos a avanzar hacia nuevos modelos de colaboración creativa centrados en las personas.
- Published
- 2024
- Full Text
- View/download PDF
6. Restricted Daily Sodium Intake as Heart Failure Management: A Systematic Review
- Author
-
Kiara Hanna Quinncilla, Eric Raditya Kaminto, Melani Limenco Benly, Anisa Rizmi Lausiri, Andreas Adiwinata Then, Rara Poetri Claudya, Hartanto Hartanto, Muhammad Juni Akbar, Christobal Anugerah Tanisa, and Nafisa Zulpa Elhapidi
- Subjects
Heart failure ,Hypertension ,Management ,New York heart association (NYHA) functional class ,Sodium restriction ,Medicine ,Medicine (General) ,R5-920 - Abstract
Objective: To evaluate mortality and morbidity in HF patients receiving sodium restriction. Study Design: Systematic Literature Review (SLR) of RCTs and Cohort studies worldwide published between Jan 2013 to Jan 2023. Methodology: We systematically selected RCTs and Cohort studies with sodium restriction as an intervention published within the last decade from five databases (PubMed, Scopus, Cochrane Library, Embase, and Medline). The full texts retrieved were assessed for risk of bias, and then a systematic review was performed. The endpoints analyzed were mortality and morbidity. Result: Five RCTs and two cohort studies were included in this study, with 2,505 participants. The endpoints retrieved were mortality and morbidity (hospitalization, NYHA functional class, BNP or NT-proBNP level, quality of life, and congestion). No improvement was seen in mortality and hospitalization, but sodium restriction improved the rest of the morbidity indicators. Over-restricted and overconsumption of sodium intake might worsen HF presentation. When analyzed based on the HF groups, there was not enough evidence to recommend sodium dose based on ejection fraction; however, there was potentially more benefit for patients with higher NYHA classes. However, more evidence is still needed. Conclusion: Sodium restriction did not benefit mortality and hospitalization but improved quality of life, systolic blood pressure, and BNP or NT-pro BNP levels in all HF classes.
- Published
- 2024
- Full Text
- View/download PDF
7. Editorial
- Author
-
Melani Lleonart and Álvaro Sanchis
- Subjects
Visual arts ,N1-9211 ,Drawing. Design. Illustration ,NC1-1940 - Abstract
Editorial del duodécimo número de Eme Magazine
- Published
- 2024
8. Sigrid Bürstmayr: diseñar para un mundo mejor
- Author
-
Álvaro Sanchis and Melani Lleonart
- Subjects
Visual arts ,N1-9211 ,Drawing. Design. Illustration ,NC1-1940 - Abstract
Sigrid Bürstmayr es profesora e investigadora en FH JOANNEUM, Universidad de Ciencias Aplicadas de Graz (Austria). Sus áreas de estudio y trabajo están relacionadas con el diseño de exposiciones, el diseño sostenible y el activismo. Valiéndose de su experiencia profesional y de su carrera docente, está profundamente comprometida con estos temas y combina teoría y praxis en su enfoque. En el aula, integra conceptos y metodologías que buscan fomentar el pensamiento crítico de las y los estudiantes sobre los retos del diseño en el siglo XXI.
- Published
- 2023
- Full Text
- View/download PDF
9. Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines
- Author
-
Marta Sanz-Álvarez, Melani Luque, Miriam Morales-Gallego, Ion Cristóbal, Natalia Ramírez-Merino, Yamileth Rangel, Yann Izarzugaza, Pilar Eroles, Joan Albanell, Juan Madoz-Gúrpide, and Federico Rojo
- Subjects
breast cancer ,HER2 positive ,targeted therapy ,trastuzumab ,pertuzumab ,resistance ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The combination of trastuzumab and pertuzumab as first-line therapy in patients with HER2-positive breast cancer has shown significant clinical benefits compared to trastuzumab alone. However, despite initial therapeutic success, most patients eventually progress, and tumors develop acquired resistance and invariably relapse. Therefore, there is an urgent need to improve our understanding of the mechanisms governing resistance in order to develop targeted therapeutic strategies with improved efficacy. We generated four novel HER2-positive cell lines via prolonged exposure to trastuzumab and pertuzumab and determined their resistance rates. Long-term resistance was confirmed by a significant increase in the colony-forming capacity of the derived cells. We authenticated the molecular identity of the new lines via both immunohistochemistry for the clinical phenotype and molecular profiling of point mutations. HER2 overexpression was confirmed in all resistant cell lines, and acquisition of resistance to trastuzumab and pertuzumab did not translate into differences in ER, PR, and HER2 receptor expression. In contrast, changes in the expression and activity of other HER family members, particularly HER4, were observed. In the same vein, analyses of the receptor and effector kinase status of different cellular pathways revealed that the MAPK pathway may be involved in the acquisition of resistance to trastuzumab and pertuzumab. Finally, proteomic analysis confirmed a significant change in the abundance patterns of more than 600 proteins with implications in key biological processes, such as ribosome formation, mitochondrial activity, and metabolism, which could be relevant mechanisms in the generation of resistance in HER2-positive breast cancer. We concluded that these resistant BCCLs may be a valuable tool to better understand the mechanisms of acquisition of resistance to trastuzumab and pertuzumab-based anti-HER2 therapy.
- Published
- 2023
- Full Text
- View/download PDF
10. Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells
- Author
-
Andrea Santos, Ion Cristóbal, Cristina Caramés, Melani Luque, Marta Sanz-Álvarez, Juan Madoz-Gúrpide, Federico Rojo, and Jesús García-Foncillas
- Subjects
miR-19b ,PPP2R5E ,CRC ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
MicroRNA (miR)-19b is deregulated in colorectal cancer (CRC) and locally advanced rectal cancer (LARC), predicting worse outcome and disease progression in CRC patients, and acting as a promising prognostic marker of patient recurrence and pathological response to 5-fluorouracil (5-FU)-based neoadjuvant chemoradiotherapy in LARC. Moreover, there is a strong inverse correlation between miR-19b and PPP2R5E in LARC, and both predict the response to neoadjuvant therapy in LARC patients. However, the functional role of the miR-19b/PPP2R5E axis in CRC cells remains to be experimentally evaluated. Here, we confirm with luciferase assays that miR-19b is a direct negative regulator of PPP2R5E in CRC, which is concordant with the observed decreased PP2A activity levels after miR-19b overexpression. Furthermore, PPP2R5E downregulation plays a key role mediating miR-19b-induced oncogenic effects, increasing cell viability, colonosphere formation ability, and the migration of CRC cells. Lastly, we also confirm the role of miR-19b mediating 5-FU sensitivity of CRC cells through negative PPP2R5E regulation. Altogether, our findings demonstrate the functional relevance of the miR-19b/PPP2R5E signaling pathway in disease progression, and its potential therapeutic value determining the 5-FU response of CRC cells.
- Published
- 2023
- Full Text
- View/download PDF
11. Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
- Author
-
Melani Luque, Marta Sanz-Álvarez, Miriam Morales-Gallego, Juan Madoz-Gúrpide, Sandra Zazo, Carolina Domínguez, Alicia Cazorla, Yann Izarzugaza, Juan Luis Arranz, Ion Cristóbal, and Federico Rojo
- Subjects
HER2-positive breast cancer ,immunotherapy ,tumor-infiltrating lymphocytes ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Human epidermal growth factor receptor 2–positive (HER2-positive) breast cancer accounts for 15 to 25% of breast cancer cases. Although therapies based on the use of monoclonal anti-HER2 antibodies present clinical benefit for a subtype of patients with HER2-positive breast cancer, more than 50% of them are unresponsive to targeted therapies or they eventually relapse. In recent years, reactivation of the adaptive immune system in patients with solid tumors has emerged as a therapeutic option with great potential for clinical benefit. Since the approval of the first treatment directed against HER2 as a therapeutic target, the range of clinical options has expanded greatly, and, in this sense, cellular immunotherapy with T cells relies on the cytotoxicity generated by these cells, which ultimately leads to antitumor activity. Lymphocytic infiltration of tumors encompasses a heterogeneous population of immune cells within the tumor microenvironment that exhibits distinct patterns of immune activation and exhaustion. The prevalence and prognostic value of tumor-infiltrating lymphocyte (TIL) counts are associated with a favorable prognosis in HER2-positive breast cancers. This review discusses emerging findings that contribute to a better understanding of the role of immune infiltrates in HER2-positive breast cancer. In addition, it summarizes the most recent results in HER2-positive breast cancer immunotherapy and anticipates which therapeutic strategies could be applied in the immediate future.
- Published
- 2022
- Full Text
- View/download PDF
12. MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients
- Author
-
Andrea Santos, Ion Cristóbal, Jaime Rubio, Cristina Caramés, Melani Luque, Marta Sanz-Álvarez, Sandra Zazo, Juan Madoz-Gúrpide, Federico Rojo, and Jesus García-Foncillas
- Subjects
miR-19b ,5-FU resistance ,progression ,locally advanced rectal cancer ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The standard clinical management of locally advanced rectal cancer (LARC) patients includes neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) followed by mesorectal excision. MicroRNA (miR)-19b expression levels in LARC biopsies obtained from initial colonoscopy have recently been identified as independent predictors of both patient outcome and pathological response to preoperative CRT in this disease. Moreover, it has been discovered that this miR increases its expression in 5-FU resistant colon cancer cells after 5-FU exposure. Despite the fact that these observations suggest a functional role of miR-19b modulating 5-FU response of LARC cells, this issue still remains to be clarified. Here, we show that downregulation of miR-19b enhances the antitumor effects of 5-FU treatment. Moreover, ectopic miR-19b modulation was able to restore sensitivity to 5-FU treatment using an acquired resistant model to this compound. Notably, we also evaluated the potential clinical impact of miR-19b as a predictive marker of disease progression after tumor surgery resection in LARC patients, observing that miR-19b overexpression significantly anticipates patient recurrence in our cohort (p = 0.002). Altogether, our findings demonstrate the functional role of miR-19b in the progressively decreasing sensitivity to 5-FU treatment and its potential usefulness as a therapeutic target to overcome 5-FU resistance, as well as its clinical impact as predictor of tumor progression and relapse.
- Published
- 2022
- Full Text
- View/download PDF
13. CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
- Author
-
Melani Luque, Ion Cristóbal, Marta Sanz-Álvarez, Andrea Santos, Sandra Zazo, Pilar Eroles, Oriol Arpí, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, Jesús García-Foncillas, and Federico Rojo
- Subjects
p-AKT ,CIP2A ,prognosis ,therapy ,early breast cancer ,Medicine - Abstract
Together with its reported ability to modulate AKT phosphorylation (p-AKT) status in several tumor types, the oncoprotein CIP2A has been described to induce breast cancer progression and drug resistance. However, the clinical and therapeutic relevance of the CIP2A/AKT interplay in breast cancer remains to be fully clarified. Here, we found high p-AKT levels in 80 out of 220 cases (36.4%), which were associated with negative estrogen receptor expression (p = 0.049) and CIP2A overexpression (p < 0.001). Interestingly, p-AKT determined substantially shorter overall (p = 0.002) and progression-free survival (p = 0.003), and multivariate analyses showed its CIP2A-independent prognostic value. Moreover, its clinical relevance was further confirmed in the triple negative and HER2-positive subgroups after stratifying our series by molecular subtype. Functionally, we confirmed in vitro the role of CIP2A as a regulator of p-AKT levels in breast cancer cell lines, and the importance of the CIP2A/AKT axis was also validated in vivo. Finally, p-AKT also showed a higher predictive value of response to doxorubicin than CIP2A in ex vivo analyses. In conclusion, our findings suggest that CIP2A overexpression is a key contributing event to AKT phosphorylation and highlights the CIP2A/AKT axis as a promising therapeutic target in breast cancer. However, our observations highlight the existence of alternative mechanisms that regulate AKT signaling in a subgroup of breast tumors without altered CIP2A expression that determines its independent value as a marker of poor outcome in this disease.
- Published
- 2022
- Full Text
- View/download PDF
14. MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer Patients
- Author
-
Andrea Santos, Ion Cristóbal, Jaime Rubio, Cristina Caramés, Melani Luque, Marta Sanz-Alvarez, Miriam Morales-Gallego, Juan Madoz-Gúrpide, Federico Rojo, and Jesús García-Foncillas
- Subjects
MiR-199b ,tumor suppressor ,prognosis ,LARC ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The identification of robust prognostic markers still represents a need in locally advanced rectal cancer (LARC). MicroRNAs (miRs) have progressively emerged as promising circulating markers, overcoming some limitations that traditional biopsy comprises. Tissue miR-199b deregulation has been reported to predict outcome and response to neoadjuvant chemoradiotherapy (nCRT) in LARC, and was also found to be associated with disease progression in colorectal cancer. However, its biological and clinical relevance remains to be fully clarified. Thus, we observed here that miR-199b regulates cell migration, aggressiveness, and cell growth, and inhibits colonosphere formation and induces caspase-dependent apoptosis. Moreover, miR-199b expression was quantified by real-time PCR in plasma samples from LARC patients and its downregulation was observed in 22.7% of cases. This alteration was found to be associated with higher tumor size (p = 0.002) and pathological stage (p = 0.020) after nCRT. Notably, we observed substantially lower global miR-199b expression associated with patient downstaging (p = 0.009), as well as in non-responders compared to those cases who responded to nCRT in both pre- (p = 0.003) and post-treatment samples (p = 0.038). In concordance, we found that miR-199b served as a predictor marker of response to neoadjuvant therapy in our cohort (p = 0.011). Altogether, our findings here demonstrate the functional relevance of miR-199b in this disease and its potential value as a novel circulating marker in LARC.
- Published
- 2022
- Full Text
- View/download PDF
15. Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer
- Author
-
Melani Luque, Marta Sanz-Álvarez, Andrea Santamaría, Sandra Zazo, Ion Cristóbal, Lorena de la Fuente, Pablo Mínguez, Pilar Eroles, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, and Federico Rojo
- Subjects
breast cancer ,HER2-positive ,tumour microenvironment ,targeted therapy ,trastuzumab ,resistance ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in patients with HER2-positive metastatic breast cancer has provided significant clinical benefits compared to trastuzumab plus docetaxel alone. However, despite the therapeutic success of existing therapies targeting HER2, tumours invariably relapse. Therefore, there is an urgent need to improve our understanding of the mechanisms governing resistance, so that specific therapeutic strategies can be developed to provide improved efficacy. It is well known that the tumour microenvironment (TME) has a significant impact on cancer behaviour. Cancer-associated fibroblasts (CAFs) are essential components of the tumour stroma that have been linked to acquired therapeutic resistance and poor prognosis in breast cancer. For this reason, it would be of interest to identify novel biomarkers in the tumour stroma that could emerge as therapeutic targets for the modulation of resistant phenotypes. Conditioned medium experiments carried out in our laboratory with CAFs derived from HER2-positive patients showed a significant capacity to promote resistance to trastuzumab plus pertuzumab therapies in two HER2-positive breast cancer cell lines (BCCLs), even in the presence of docetaxel. In order to elucidate the components of the CAF-conditioned medium that may be relevant in the promotion of BCCL resistance, we implemented a multiomics strategy to identify cytokines, transcription factors, kinases and miRNAs in the secretome that have specific targets in cancer cells. The combination of cytokine arrays, label-free LC-MS/MS quantification and miRNA analysis to explore the secretome of CAFs under treatment conditions revealed several up- and downregulated candidates. We discuss the potential role of some of the most interesting candidates in generating resistance in HER2-positive breast cancer.
- Published
- 2021
- Full Text
- View/download PDF
16. Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients
- Author
-
Ion Cristóbal, Andrea Santos, Jaime Rubio, Cristina Caramés, Sandra Zazo, Marta Sanz-Álvarez, Melani Luque, Juan Madoz-Gúrpide, Federico Rojo, and Jesús García-Foncillas
- Subjects
MiR-199b ,locally advanced rectal cancer ,prognosis ,pathological response ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The absence of established predictive markers with value to anticipate response to neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) represents a current major challenge in locally advanced rectal cancer (LARC). The tumor suppressor microRNA (miR)-199b has been reported to play a key role determining 5-FU sensitivity of colorectal cancer cells through the regulation of several signaling pathways, and has emerged as a novel molecular target to overcome the 5-FU resistant phenotype. Moreover, miR-199b downregulation was described as a common alteration that predicts lack of response to preoperative CRT in LARC but this issue needs to be confirmed in independent larger cohorts. Here, we evaluate the clinical impact of miR-199b in LARC and perform additional analyses to further clarify its potential relevance as novel marker in this disease. Thus, miR-199b expression was quantified by real-time-PCR in a cohort of 185 LARC patients, observing this miR downregulated in 22.2% of cases and significantly associated with higher tumor size (p = 0.026) and positive lymph node after CRT (p = 0.005), and higher pathological stage (p = 0.004). Notably, this alteration showed a strong independent predictive value of poor pathological response to neoadjuvant CRT (p = 0.004). Moreover, the subgroup of cases with low miR-199b levels had a markedly shorter overall (p < 001) and event-free survival (p < 0.001), and multivariate analyses showed that miR-199b deregulation represents an independent prognosticator for patient outcome in LARC. Interestingly, the prognostic impact of this miR was strongly significant in both younger and elderly patients, and was very effective determining patient recurrence (p = 0.004). Finally, we compared miR-199b expression profiles in a set of cases with pre and post-treatment samples available, observing that only a minimal response leads to miR-199b increase levels, further suggesting its potential clinical and therapeutic relevance as a promising marker and novel molecular target for the management of LARC.
- Published
- 2021
- Full Text
- View/download PDF
17. Potential Cell-Based and Cell-Free Therapy for Patients with COVID-19.
- Author
-
Tan MI, Alfarafisa NM, Septiani P, Barlian A, Firmansyah M, Faizal A, Melani L, and Nugrahapraja H
- Subjects
- Cell- and Tissue-Based Therapy, Humans, SARS-CoV-2, COVID-19 therapy, Mesenchymal Stem Cell Transplantation adverse effects, Mesenchymal Stem Cells
- Abstract
Since it was first reported, the novel coronavirus disease 2019 (COVID-19) remains an unresolved puzzle for biomedical researchers in different fields. Various treatments, drugs, and interventions were explored as treatments for COVID. Nevertheless, there are no standard and effective therapeutic measures. Meanwhile, mesenchymal stem cell (MSC) therapy offers a new approach with minimal side effects. MSCs and MSC-based products possess several biological properties that potentially alleviate COVID-19 symptoms. Generally, there are three classifications of stem cell therapy: cell-based therapy, tissue engineering, and cell-free therapy. This review discusses the MSC-based and cell-free therapies for patients with COVID-19, their potential mechanisms of action, and clinical trials related to these therapies. Cell-based therapies involve the direct use and injection of MSCs into the target tissue or organ. On the other hand, cell-free therapy uses secreted products from cells as the primary material. Cell-free therapy materials can comprise cell secretomes and extracellular vesicles. Each therapeutic approach possesses different benefits and various risks. A better understanding of MSC-based and cell-free therapies is essential for supporting the development of safe and effective COVID-19 therapy.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.